After a clinical study established proof of concept for local intramuscular administration of drisapersen in DMD [21], subcutaneous (sc) drisapersen was administered to 12 male subjects with DMD in an open-label, dose-escalation study, with dose-related novel dystrophin expression [22]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.